B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-08-11Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…
-
CLINICAL_TRIALS research · 2016-06-09Clinical Trial Update: CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies [Phase 1, Phase 2]
This entry reports a phase 1/2 clinical trial of a CD22-targeted CAR-T therapy for recurrent or refractory B-cell malignancies; the status i…
-
CLINICAL_TRIALS trial_result · 2016-06-07Clinical Trial Update: Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma [Phase 1]
Phase 1 study of the combination of inotuzumab ozogamicin and temsirolimus in relapsed or refractory CD22+ B-cell non-Hodgkin lymphoma has c…
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: A Phase I/II Trial of VR-CHOP in Lymphoma Patients [Phase 1, Phase 2]
This clinical trial update reports results from a Phase I/II study of VR-CHOP in patients with B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial update evaluating Zevalin in combination with BuCyE high-dose therapy for B-cell non-Hodgkin lymphoma; the study status is c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-12-09Clinical Trial Update: Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]
This trial evaluated safety and tolerability of inotuzumab ozogamicin in Japanese patients with B-cell non-Hodgkin lymphoma; the Phase 1 stu…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL [Phase 2]
Phase 2 trial evaluating dose-augmented rituximab with ICE chemotherapy in patients with primary refractory or poor-risk relapsed aggressive…
-
CLINICAL_TRIALS research · 2015-08-20Clinical Trial Update: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection [Phase 1]
A terminated Phase 1 clinical trial evaluated ibrutinib for relapsed or refractory B-cell non-Hodgkin lymphoma in adults with HIV infection.
-
CLINICAL_TRIALS research · 2015-05-28Clinical Trial Update: A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 pharmacokinetic study comparing SCT400 with rituximab in patients with B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2015-04-30Clinical Trial Update: Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial update of Bryostatin-1 in combination with Rituximab for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leuk…
-
CLINICAL_TRIALS research · 2014-11-06Clinical Trial Update: Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes [Phase 1, Phase 2]
This entry provides an update on a phase 1/2 gene therapy trial using CD19 CAR-T cells to treat relapsed or refractory B-cell non-Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This ClinicalTrials.gov update reports a terminated phase 1/2 trial evaluating fenretinide with rituximab for B-cell non-Hodgkin lymphomas; …
-
CLINICAL_TRIALS trial_result · 2014-08-01Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. [Phase 1]
Phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of a recombinant chimeric anti-CD20 monoclonal antibody in patients …
-
CLINICAL_TRIALS research · 2014-07-24Clinical Trial Update: S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma
This clinical trial update reports a completed study examining gene analyses in tissue samples from patients with B-cell non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2013-07-11Clinical Trial Update: Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial evaluated the combination of epirubicin and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma or…
-
CLINICAL_TRIALS trial_result · 2013-06-25Clinical Trial Update: Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers [Phase 2]
This Phase 2 trial update reports on the use of pentostatin, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia a…
-
CLINICAL_TRIALS trial_result · 2013-05-22Clinical Trial Update: Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]
This Phase 1 trial of MDX-1203 in patients with clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma has comp…
-
CLINICAL_TRIALS trial_result · 2013-04-15Clinical Trial Update: Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update reporting completion and posted results for chemotherapy with a monoclonal antibody and radioimmunotherapy in high-risk…
-
CLINICAL_TRIALS research · 2012-08-28Clinical Trial Update: Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of a Rituximab, Fludarabine, Cyclophosphamide, and Yttrium-90 ibritumomab tiuxetan re…
-
CLINICAL_TRIALS trial_result · 2012-07-09Clinical Trial Update: Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) [Phase 1, Phase 2]
This update summarizes Phase 1/2 trial results for clo farabine in relapsed or refractory T-cell or B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2012-03-14Clinical Trial Update: A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial update for ONTAK (denileukin diftitox) in relapsed or refractory B-cell non-Hodgkin lymphoma; the study has completed…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma [Phase 1]
Phase 1 multi-dose escalation trial evaluating the safety and pharmacokinetics of SAR3419 as a single agent in relapsed/refractory B-cell no…
-
CLINICAL_TRIALS trial_result · 2011-07-26Clinical Trial Update: Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 trial evaluating Velcade (bortezomib) in combination with Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has bee…
-
CLINICAL_TRIALS trial_result · 2010-07-30Clinical Trial Update: Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma [Phase 2]
This update reports a phase 2 salvage therapy trial of idarubicin for relapsing primary central nervous system lymphoma, sponsored by IELSG,…
-
CLINICAL_TRIALS trial_result · 2009-06-25Clinical Trial Update: Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) [Phase 2]
This is an interventional Phase 2 trial evaluating a pentostatin, cyclophosphamide, and rituximab regimen for indolent B-cell non-Hodgkin ly…